Company intelligence / Profile preview
Jasper Therapeutics, Inc.
Redwood City, California, United Statesjaspertx.com ↗
- Ownership
- Public · JSPR
- Development stage
- Other
01
Overview
Briquilimab has demonstrated efficacy and safety in over 160 dosed subjects and healthy volunteers. Positive data has been reported from the BEACON study in CSU and the SPOTLIGHT study in CIndU, showing rapid and deep response profiles in patients with chronic urticaria. The company is advancing briquilimab into a pivotal program in CSU with a Phase 2b study expected to commence in 2025.
- Therapeutic areas
- PulmonologyOncologyImmunologyDermatologyHematology
- Modalities
- Monoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Financials
- Market cap
- $15.6M
- Total revenue
- $0
- Enterprise value
- $8.6M
Beyond the preview
Go deeper on Jasper Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jasper Therapeutics, Inc..